Tenax Patent Broadening IP Protection for Levosimendan in Pulmonary Hypertension with Heart Failure OKd

 Once granted, this patent will:

• provide U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040
• broaden IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF
• expressly provide IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF
• expressly provide IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-HFpEF
• represent the third patent granted to Tenax since March of 2023 protecting the use of levosimendan in the treatment of PH-HFpEF

https://www.globenewswire.com/news-release/2024/02/06/2824335/0/en/Tenax-Therapeutics-Announces-USPTO-Grants-Notice-of-Allowance-for-U-S-Patent-Application-Significantly-Broadening-IP-Protection-for-Use-of-Levosimendan-in-Pulmonary-Hypertension-wi.html